TRIDENT 2.0
Brief description of study
Primary Objective
--To evaluate the hypothesis that the SGLT2 inhibitor, dapagliflozin, alters kidney molecular pathways associated with progression of diabetic kidney disease
Secondary Objectives
--To evaluate relationships between changes in kidney molecular fingerprints and changes in kidney function
--To identify factors associated with changes in kidney molecular fingerprints
--To evaluate the willingness of individuals to have a non-clinically indicated kidney biopsy in order to evaluate the feasibility of future larger studies The primary outcome is the change in kidney tissue molecular fingerprint from baseline to 18 months Secondary outcomes include:
--Change in eGFR from baseline to 18 months
--Change in proteinuria / albuminuria from baseline to 18 months
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
